Loading…

Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants

Anticoagulant therapy has undergone a significant change since direct oral anticoagulants (DOACs) introduction. Their obvious advantages including the fixed dose, the few interactions and less frequent controls, have made them the first choice anticoagulant therapy. More and more patients have there...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and thrombolysis 2020-10, Vol.50 (3), p.718-723
Main Authors: Serrao, Alessandra, Lucani, Benedetta, Assanto Manfredi, Giovanni, Fiori, Luciano, Baldacci, Erminia, Aprile, Simona Michela, Chistolini, Antonio
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c347t-20afaee87d4d54e0e83f090add6e7806ba3ea9e72767bbea6644ae0a206fccc03
cites cdi_FETCH-LOGICAL-c347t-20afaee87d4d54e0e83f090add6e7806ba3ea9e72767bbea6644ae0a206fccc03
container_end_page 723
container_issue 3
container_start_page 718
container_title Journal of thrombosis and thrombolysis
container_volume 50
creator Serrao, Alessandra
Lucani, Benedetta
Assanto Manfredi, Giovanni
Fiori, Luciano
Baldacci, Erminia
Aprile, Simona Michela
Chistolini, Antonio
description Anticoagulant therapy has undergone a significant change since direct oral anticoagulants (DOACs) introduction. Their obvious advantages including the fixed dose, the few interactions and less frequent controls, have made them the first choice anticoagulant therapy. More and more patients have therefore switched from therapy with vitamin K antagonists (VKAs) to DOACs. Aim of our study was to assess the satisfaction, quality of life (QoL) and therapy adherence of patients who switched from VKA to DOACs therapy. This single center study evaluated satisfaction and QoL of 107 patients who switched from VKA to DOACs therapy through Anti-Clot Treatment Scale and SF-36 respectively. The questionnaires were administered before therapy change, after 3 months of DOACs therapy and then annually. We also evaluated DOACs therapy adherence with a questionnaire administered each visit and through the measures of DOACs plasma levels. Patients’ satisfaction and QoL were high during VKA therapy, but with DOACs we observed an improvement after the first 3 months and then maintained over the time of DOACs therapy. DOACs adherence was excellent, also confirmed by DOACs plasma levels.
doi_str_mv 10.1007/s11239-020-02070-2
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2369413386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2369413386</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-20afaee87d4d54e0e83f090add6e7806ba3ea9e72767bbea6644ae0a206fccc03</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi1ERbcLL8AB-ciBwMTOxpsjqgpFVOLQInGzZp3J4iqxtx4HaZ-Fl62XFI4cLI9mvvlk6xfidQ3vawDzgeta6a4CBadjoFLPxKreGF2ZRv14LlbQqa7aaNiciwvmewDoOlAvxLlWZVVBvRK_bzF7HtBlH8M7-TDj6PNRxkGOfiCJoZf5JyU8HCX2paDgSpeZmCcKWfogE-G40IfiKk2WOWFgf1L6sJdDipP85TNOhf5anBn3ZcInMMreJ3JZxlQsZeRdxP08lopfirMBR6ZXT_dafP90dXd5Xd18-_zl8uNN5XRjcqUAByTamr7pNw0BbfUAHWDft2S20O5QE3ZklGnNbkfYtk2DBKigHZxzoNfi7eI9pPgwE2c7eXY0lkdQnNkq3XZNrfW2LahaUJcic6LBHpKfMB1tDfYUil1CsSUQ-yeUsr0Wb578826i_t_K3xQKoBeAyyjsKdn7OKdQ_vw_7SPPNZxr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2369413386</pqid></control><display><type>article</type><title>Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants</title><source>Springer Nature</source><creator>Serrao, Alessandra ; Lucani, Benedetta ; Assanto Manfredi, Giovanni ; Fiori, Luciano ; Baldacci, Erminia ; Aprile, Simona Michela ; Chistolini, Antonio</creator><creatorcontrib>Serrao, Alessandra ; Lucani, Benedetta ; Assanto Manfredi, Giovanni ; Fiori, Luciano ; Baldacci, Erminia ; Aprile, Simona Michela ; Chistolini, Antonio</creatorcontrib><description>Anticoagulant therapy has undergone a significant change since direct oral anticoagulants (DOACs) introduction. Their obvious advantages including the fixed dose, the few interactions and less frequent controls, have made them the first choice anticoagulant therapy. More and more patients have therefore switched from therapy with vitamin K antagonists (VKAs) to DOACs. Aim of our study was to assess the satisfaction, quality of life (QoL) and therapy adherence of patients who switched from VKA to DOACs therapy. This single center study evaluated satisfaction and QoL of 107 patients who switched from VKA to DOACs therapy through Anti-Clot Treatment Scale and SF-36 respectively. The questionnaires were administered before therapy change, after 3 months of DOACs therapy and then annually. We also evaluated DOACs therapy adherence with a questionnaire administered each visit and through the measures of DOACs plasma levels. Patients’ satisfaction and QoL were high during VKA therapy, but with DOACs we observed an improvement after the first 3 months and then maintained over the time of DOACs therapy. DOACs adherence was excellent, also confirmed by DOACs plasma levels.</description><identifier>ISSN: 0929-5305</identifier><identifier>EISSN: 1573-742X</identifier><identifier>DOI: 10.1007/s11239-020-02070-2</identifier><identifier>PMID: 32112201</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Cardiology ; Hematology ; Medicine ; Medicine &amp; Public Health</subject><ispartof>Journal of thrombosis and thrombolysis, 2020-10, Vol.50 (3), p.718-723</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-20afaee87d4d54e0e83f090add6e7806ba3ea9e72767bbea6644ae0a206fccc03</citedby><cites>FETCH-LOGICAL-c347t-20afaee87d4d54e0e83f090add6e7806ba3ea9e72767bbea6644ae0a206fccc03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32112201$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Serrao, Alessandra</creatorcontrib><creatorcontrib>Lucani, Benedetta</creatorcontrib><creatorcontrib>Assanto Manfredi, Giovanni</creatorcontrib><creatorcontrib>Fiori, Luciano</creatorcontrib><creatorcontrib>Baldacci, Erminia</creatorcontrib><creatorcontrib>Aprile, Simona Michela</creatorcontrib><creatorcontrib>Chistolini, Antonio</creatorcontrib><title>Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants</title><title>Journal of thrombosis and thrombolysis</title><addtitle>J Thromb Thrombolysis</addtitle><addtitle>J Thromb Thrombolysis</addtitle><description>Anticoagulant therapy has undergone a significant change since direct oral anticoagulants (DOACs) introduction. Their obvious advantages including the fixed dose, the few interactions and less frequent controls, have made them the first choice anticoagulant therapy. More and more patients have therefore switched from therapy with vitamin K antagonists (VKAs) to DOACs. Aim of our study was to assess the satisfaction, quality of life (QoL) and therapy adherence of patients who switched from VKA to DOACs therapy. This single center study evaluated satisfaction and QoL of 107 patients who switched from VKA to DOACs therapy through Anti-Clot Treatment Scale and SF-36 respectively. The questionnaires were administered before therapy change, after 3 months of DOACs therapy and then annually. We also evaluated DOACs therapy adherence with a questionnaire administered each visit and through the measures of DOACs plasma levels. Patients’ satisfaction and QoL were high during VKA therapy, but with DOACs we observed an improvement after the first 3 months and then maintained over the time of DOACs therapy. DOACs adherence was excellent, also confirmed by DOACs plasma levels.</description><subject>Cardiology</subject><subject>Hematology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><issn>0929-5305</issn><issn>1573-742X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAQhi1ERbcLL8AB-ciBwMTOxpsjqgpFVOLQInGzZp3J4iqxtx4HaZ-Fl62XFI4cLI9mvvlk6xfidQ3vawDzgeta6a4CBadjoFLPxKreGF2ZRv14LlbQqa7aaNiciwvmewDoOlAvxLlWZVVBvRK_bzF7HtBlH8M7-TDj6PNRxkGOfiCJoZf5JyU8HCX2paDgSpeZmCcKWfogE-G40IfiKk2WOWFgf1L6sJdDipP85TNOhf5anBn3ZcInMMreJ3JZxlQsZeRdxP08lopfirMBR6ZXT_dafP90dXd5Xd18-_zl8uNN5XRjcqUAByTamr7pNw0BbfUAHWDft2S20O5QE3ZklGnNbkfYtk2DBKigHZxzoNfi7eI9pPgwE2c7eXY0lkdQnNkq3XZNrfW2LahaUJcic6LBHpKfMB1tDfYUil1CsSUQ-yeUsr0Wb578826i_t_K3xQKoBeAyyjsKdn7OKdQ_vw_7SPPNZxr</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Serrao, Alessandra</creator><creator>Lucani, Benedetta</creator><creator>Assanto Manfredi, Giovanni</creator><creator>Fiori, Luciano</creator><creator>Baldacci, Erminia</creator><creator>Aprile, Simona Michela</creator><creator>Chistolini, Antonio</creator><general>Springer US</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20201001</creationdate><title>Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants</title><author>Serrao, Alessandra ; Lucani, Benedetta ; Assanto Manfredi, Giovanni ; Fiori, Luciano ; Baldacci, Erminia ; Aprile, Simona Michela ; Chistolini, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-20afaee87d4d54e0e83f090add6e7806ba3ea9e72767bbea6644ae0a206fccc03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cardiology</topic><topic>Hematology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Serrao, Alessandra</creatorcontrib><creatorcontrib>Lucani, Benedetta</creatorcontrib><creatorcontrib>Assanto Manfredi, Giovanni</creatorcontrib><creatorcontrib>Fiori, Luciano</creatorcontrib><creatorcontrib>Baldacci, Erminia</creatorcontrib><creatorcontrib>Aprile, Simona Michela</creatorcontrib><creatorcontrib>Chistolini, Antonio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and thrombolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Serrao, Alessandra</au><au>Lucani, Benedetta</au><au>Assanto Manfredi, Giovanni</au><au>Fiori, Luciano</au><au>Baldacci, Erminia</au><au>Aprile, Simona Michela</au><au>Chistolini, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants</atitle><jtitle>Journal of thrombosis and thrombolysis</jtitle><stitle>J Thromb Thrombolysis</stitle><addtitle>J Thromb Thrombolysis</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>50</volume><issue>3</issue><spage>718</spage><epage>723</epage><pages>718-723</pages><issn>0929-5305</issn><eissn>1573-742X</eissn><abstract>Anticoagulant therapy has undergone a significant change since direct oral anticoagulants (DOACs) introduction. Their obvious advantages including the fixed dose, the few interactions and less frequent controls, have made them the first choice anticoagulant therapy. More and more patients have therefore switched from therapy with vitamin K antagonists (VKAs) to DOACs. Aim of our study was to assess the satisfaction, quality of life (QoL) and therapy adherence of patients who switched from VKA to DOACs therapy. This single center study evaluated satisfaction and QoL of 107 patients who switched from VKA to DOACs therapy through Anti-Clot Treatment Scale and SF-36 respectively. The questionnaires were administered before therapy change, after 3 months of DOACs therapy and then annually. We also evaluated DOACs therapy adherence with a questionnaire administered each visit and through the measures of DOACs plasma levels. Patients’ satisfaction and QoL were high during VKA therapy, but with DOACs we observed an improvement after the first 3 months and then maintained over the time of DOACs therapy. DOACs adherence was excellent, also confirmed by DOACs plasma levels.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32112201</pmid><doi>10.1007/s11239-020-02070-2</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0929-5305
ispartof Journal of thrombosis and thrombolysis, 2020-10, Vol.50 (3), p.718-723
issn 0929-5305
1573-742X
language eng
recordid cdi_proquest_miscellaneous_2369413386
source Springer Nature
subjects Cardiology
Hematology
Medicine
Medicine & Public Health
title Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T21%3A54%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Satisfaction,%20quality%20of%20life%20and%20therapy%20adherence%20assessment%20in%20real%20life%20patients%20transitioning%20from%20vitamin%20K%20antagonists%20to%20direct%20oral%20anticoagulants&rft.jtitle=Journal%20of%20thrombosis%20and%20thrombolysis&rft.au=Serrao,%20Alessandra&rft.date=2020-10-01&rft.volume=50&rft.issue=3&rft.spage=718&rft.epage=723&rft.pages=718-723&rft.issn=0929-5305&rft.eissn=1573-742X&rft_id=info:doi/10.1007/s11239-020-02070-2&rft_dat=%3Cproquest_cross%3E2369413386%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c347t-20afaee87d4d54e0e83f090add6e7806ba3ea9e72767bbea6644ae0a206fccc03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2369413386&rft_id=info:pmid/32112201&rfr_iscdi=true